Abstract:Background: Non-small cell lung carcinoma (NSCLC) is often fatal; advanced NSCLC has a 5-year survival rate less than 20%. Platinum-based chemotherapy, in particular, cis-diamminedichloroplatinum (II) (cisplatin or DDP), is employed for the treatment of NSCLC; however, the drug resistance occurs frequently. Autophagy is defined as the process of intracellular degradation of cytoplasmic materials in the lysosome; however, the correlation between autophagy and drug resistance remains controversial. Herein, we investigated the correlation between autophagy and cisplatin resistance and also explored the underlying mechanisms. Methods and Results: We demonstrated that DDP-resistant NSCLC A549 (A549/DDP) cells had higher autophagy activity in comparison with its parental A549 cells; DDP treatment induced a time- and dose-dependent decrease of autophagy. Intriguingly, inhibition of autophagy with pharmacological drugs or knockdown of ATG5 or Beclin-1 aggravated cell death induced by DDP treatment, indicating that autophagy played protective roles during DDP treatment. Further mechanistic investigation revealed that DDP treatment could decrease the mRNA expression level of key autophagy-related genes, such as ATG5, Beclin-1, and ATG7, suggesting DDP repressed autophagy at the transcriptional level. The MiTF/TFE family (including TFEB, TFE3, TFEC, and MiTF) were involved in nutrient sensing and organelle biogenesis, and specifically, the lysosomal biogenesis. We found that only MiTF was dramatically decreased upon DDP treatment, and also a profound decrease of lysosomal markers, LAMP-1 or LAMP-2, suggesting that MiTF was involved in the modulation of lysosomal biogenesis and, consequently, the autophagy. Moreover, the knockdown of MiTF resulted in more severe cell death in A549/DDP cells, indicting the substantial correlation between MiTF and cisplatin chemoresistance. Conclusion: Our study provides novel insights into the association between MiTF and DDP chemoresistance in NSCLC cells, and suggests targeting MiTF and/or autophagy might be a potential strategy for the reversal of DDP chemoresistance for NSCLC treatment.

Mitophagy-Mediated Tumor Dormancy Protects Cancer Cells from Chemotherapy

The metabolic flexibility of quiescent CSC: implications for chemotherapy resistance

Targeting the Mitochondria with Pseudo- Stealthy Nanotaxanes to Impair Mitochondrial Biogenesis for Effective Cancer Treatment

Doxorubicin-induced Mitophagy Contributes to Drug Resistance in Cancer Stem Cells from HCT8 Human Colorectal Cancer Cells.

The role of cancer cell bioenergetics in dormancy and drug resistance

Inhibition of NPC1L1 disrupts adaptive responses of drug-tolerant persister cells to chemotherapy

Mitochondrial Fuel Dependence on Glutamine Drives Chemo-Resistance in the Cancer Stem Cells of Hepatocellular Carcinoma

Harnessing redox signaling to overcome therapeutic-resistant cancer dormancy

Reregulated Mitochondrial Dysfunction Reverses Cisplatin Resistance Microenvironment in Colorectal Cancer

PINK1-mediated mitophagy promotes oxidative phosphorylation and redox homeostasis to induce drug-tolerant persister cancer cells

An Embryonic Diapause-like Adaptation with Suppressed Myc Activity Enables Tumor Treatment Persistence

Targeting CRL4 Suppresses Chemoresistant Ovarian Cancer Growth by Inducing Mitophagy

Nanoparticle-facilitated autophagy inhibition promotes the efficacy of chemotherapeutics against breast cancer stem cells

Metabolic Reprogramming of Chemoresistant Cancer Cells and the Potential Significance of Metabolic Regulation in the Reversal of Cancer Chemoresistance

Suppression of DRP1‑mediated Mitophagy Increases the Apoptosis of Hepatocellular Carcinoma Cells in the Setting of Chemotherapy.

A Biodegradable Nanodrug with Highly Efficient Treatment Effect by Remodeling Tumor Microenvironment and Manipulating Energy Metabolism Against Colorectal Cancer

Activation of Anaphase-Promoting Complex by P53 Induces A State of Dormancy in Cancer Cells Against Chemotherapeutic Stress

Diapause-like Drug-Tolerant Persister State: the Key to Nirvana Rebirth

Redox Control of the Dormant Cancer Cell Life Cycle

MiTF is Associated with Chemoresistance to Cisplatin in A549 Lung Cancer Cells via Modulating Lysosomal Biogenesis and Autophagy

Exosomal DEK removes chemoradiotherapy resistance by triggering quiescence exit of breast cancer stem cells